BioArctic AB (publ) (STO:BIOA.B)
276.00
-8.20 (-2.89%)
Nov 5, 2025, 11:04 AM CET
BioArctic AB Revenue
BioArctic AB had revenue of 392.12M SEK in the quarter ending June 30, 2025, with 686.69% growth. This brings the company's revenue in the last twelve months to 1.86B, up 521.22% year-over-year. In the year 2024, BioArctic AB had annual revenue of 257.35M, down -58.22%.
Revenue (ttm)
1.86B
Revenue Growth
+521.22%
P/S Ratio
13.55
Revenue / Employee
15.63M
Employees
107
Market Cap
25.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 257.35M | -358.64M | -58.22% |
| Dec 31, 2023 | 616.00M | 386.56M | 168.49% |
| Dec 31, 2022 | 229.43M | 203.77M | 794.02% |
| Dec 31, 2021 | 25.66M | -39.54M | -60.64% |
| Dec 31, 2020 | 65.21M | -217.74M | -76.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Getinge AB | 35.85B |
| Swedish Orphan Biovitrum AB | 27.85B |
| Medicover AB | 25.22B |
| Elekta AB | 17.84B |
| Asker Healthcare Group AB | 15.88B |
| AddLife AB | 10.53B |
| Nolato AB | 9.57B |
| Vimian Group AB | 4.65B |
BioArctic AB News
- 1 day ago - Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET - PRNewsWire
- 6 days ago - Sales of Leqembi® totaled 18 billion yen in the third quarter 2025 - PRNewsWire
- 9 days ago - Health Canada Grants Authorization for Leqembi® (lecanemab) - PRNewsWire
- 22 days ago - Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025 - PRNewsWire
- 4 weeks ago - Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S. - PRNewsWire
- 5 weeks ago - Leqembi® approved for IV maintenance treatment in China - PRNewsWire
- 6 weeks ago - Leqembi® approved for the treatment of early Alzheimer's disease in Australia - Benzinga
- 6 weeks ago - Leqembi® approved for the treatment of early Alzheimer's disease in Australia - PRNewsWire